Skip to main content
PMC home page
Scientific Reports logoLink to Scientific Reports
. 2020 Feb 28;10:3690. doi: 10.1038/s41598-020-60452-1

A mouse model of pulmonary Mycobacteroides abscessus infection

Emily C Maggioncalda 1, Elizabeth Story-Roller 1, Julian Mylius 2, Peter Illei 3,4, Randall J Basaraba 2, Gyanu Lamichhane 1,✉
PMCID: PMC7048719  PMID: 32111900

Abstract

There is no preclinical mouse model to investigate pulmonary Mycobacteroides abscessus (formerly Mycobacterium abscessus) infection in an immunocompetent mouse strain, especially in the context of antibiotic testing and regimen development. We developed a mouse model of pulmonary M. abscessus infection using the aerosolized route of infection that leads to an increase in bacterial burden post- implantation and develops pathology as a result. In this mouse model, treatment with corticosteroid allows for initial proliferation and sustained M. abscessus pulmonary infection and permits evaluation of efficacies of antibiotics. Administration of corticosteroids that permitted higher levels of bacterial burden in the lungs were more likely to have pathology. Treatment of mice with antibiotics administered intranasally or subcutaneously significantly reduced lung M. abscessus burden. In addition to the reference strain, independent clinical isolates of M. abscessus also readily establish infection and proliferate in the lungs of mice in this model.

Subject terms: Animal disease models, Pathogens

Introduction

In the setting of structural lung conditions such as cystic fibrosis, bronchiectasis, and COPD, Mycobacteroides abscessus (formerly Mycobacterium abscessus) can cause chronic pulmonary infection1,2 that is often incurable and associated with rapid lung function decline3–5. There is a current interest in developing new drugs and regimens to treat M. abscessus infection, as the cure rate with existing antibiotics is only 30–50%6. While there have been many exciting demonstrations of in vitro potencies of antibiotics against M. abscessus7–13, it has also been established that potency observed in vitro for M. abscessus often does not translate to an equivalent clinical efficacy in the case of pulmonary infections3. This highlights the need for a preclinical animal model to evaluate experimental antibiotics. A mammalian model that recapitulates aerosol infection leading to progressive M. abscessus burden and development of lung pathology as observed in human disease would facilitate preclinical studies of antibiotic efficacy and M. abscessus genetic determinants for virulence.

In investigations of Mycobacterium tuberculosis (M. tuberculosis), several studies have demonstrated that aerosol infected C3HeB/FeJ mice closely mimic human pulmonary pathology14–17. However, when infected with M. abscessus, these mice are able to clear the infection18. Other immunocompetent mouse strains also clear the infection over time, although certain genetically manipulated immunocompromised strains were able to maintain bacterial burden19–22. This is a compromise in favor of perpetuating the infection, but at a loss of immune cells and inflammatory markers normally observed in response to infection. Therefore, as mice are unable to mount an immune response, this precludes evaluation of critical aspects of host-pathogen interactions and pathology development that may impact efficacy of antibiotic treatments.

We hypothesized that transient pharmacologically-induced immune suppression of immunocompetent mice such as the C3HeB/FeJ strain may allow for proliferation of M. abscessus during the acute stage of infection, followed by a sustained infection that leads to development of pathologic lesions. There are precedents to support this hypothesis. In the Cornell model of latent tuberculosis23, corticosteroid use permits proliferation of M. tuberculosis24. Corticosteroid use is also a risk factor for development of invasive infections with rapidly-growing mycobacteria25–27. We applied these concepts by administering corticosteroids to mice to increase their susceptibility to an initial infection with M. abscessus.

Recently, we demonstrated proof-of-concept of the utility of pharmacological immunosuppression of C3HeB/FeJ mice to evaluate efficacies of subcutaneously delivered dual β-lactam regimens to treat pulmonary M. abscessus infection28. However, in this previous study we did not investigate how pathology develops during steroid treatment and upon steroid treatment release. Additionally, with the recent success of liposomal amikacin for inhalation in treating refractory Mycobacterium avium complex (MAC) infection29, we also tested the utility of our model for evaluation of alternative routes of antibiotic delivery, such as intranasal administration. Finally, we assessed infection and growth profiles of six additional M. abscessus strains isolated from cystic fibrosis patients.

Here, we describe a mouse model of aerosolized pulmonary M. abscessus infection with associated lung pathology. We also demonstrate its utility in evaluating efficacy of antibiotic therapies administered via the intranasal route as well as infection with clinical strains of M. abscessus, both of which have not been previously described with this model.

Methods

Ethics

Animal procedures were performed in adherence to national and Johns Hopkins University Animal Care and Use Committee guidelines, and were approved by the Johns Hopkins University Animal Care and Use Committee (animal protocol number MO17M279).

Bacterial strains and growth conditions

Mycobacteroides abscessus reference strain ATCC 19977 was used and cultured as published previously28. We also evaluated six clinical de-identified M. abscessus strains archived in the Clinical Microbiology Laboratory of the Johns Hopkins University Hospital. These strains are 5 N, 202, 214, 215, JHH4, and JHHKB and their susceptibilities to antibiotics commonly used to treat M. abscessus disease have been characterized30. Additionally, these strains were authenticated by sequencing their whole genome using Illumina 2 × 300 platform. Lungs, liver and spleen were collected aseptically and CFU enumerated; these procedures are described in more detail in the supplemental information.

Mouse infections and treatment

Female C3HeB/FeJ mice, 4–5 weeks old, were procured from Jackson Laboratories. To achieve an implantation of ~3.0–3.5 log10 CFU in the lungs of a mouse, a primary M. abscessus culture at exponential phase, A600nm of 1.00–1.20, was used to prepare a suspension by diluting to a calculated A600nm of 0.1 in Middlebrook 7H9 broth prewarmed to 37 °C. Infections were performed by aerosolizing 10 mL of this suspension using a Glas-Col Inhalation Exposure System (Glas-Col, Terre Haute, Indiana), as per the manufacturer’s instructions. The infection cycle comprised of 15 minutes of pre-heat, 30 minutes of nebulization, 30 minutes of cloud decay and 15 minutes of surface decontamination.

Suspensions of cortisone (Sigma-Aldrich C2755) and dexamethasone (Sigma-Aldrich D1756) were prepared immediately prior to administration in sterile 1x phosphate buffered saline, pH 7.4 (Quality Biological, 114-058-101). A 200 μL bolus of either corticosteroid was administered by subcutaneous injection in the dorsal abdominal flank using a 26 gauge syringe. Calculations for dosage were made assuming a 25 g mouse. No treatments were performed on the day of infection with M. abscessus. Figure 1A provides an outline of the study. More details of the study can be found in Table S1. Corticosteroid dosing strategies for this experiment were based on prior experiments with aerosolized M. abscessus mouse infection (Figs. S1–S3) as well as information from the literature24,31–33. The DXA dosing scheme was used for the clinical strain infection experiment, with sacrifices only at day 0, week 1 and week 3.

Figure 1.

Figure 1

Open in a new tab

(A) Outline of corticosteroid dosages, dosing frequency, and duration of administration. X in X/7 indicates days of treatment per week. Treatments began one week prior to infection. The treatment group naming convention is as follows: first two letters indicate corticosteroid administered (CN = cortisone, DX = dexamethasone), third letter indicates a different treatment regimen using that corticosteroid (A or B for cortisone or A, B, or C for dexamethasone). Duration of treatment is indicated by length of the lines, with changes in regimen indicated by line segmentation at the relevant time points. As controls, mice that did not receive corticosteroids were also included. Sacrifices were performed 24 hours post infection (D0) and then at weeks 1, 3, 5 and 7 post infection. (B) Study and treatment outline for testing the efficacy of intranasal administration of biapenem in comparison to subcutaneous administration. Mice were sacrificed 24 hours post infection (D0) to enumerate implantation, at 1 week post infection to enumerate bacterial burden prior to antibiotic treatment period, and then at 2 weeks post infection/1 week post antibiotic treatment to evaluate treatment efficacies.

Antibiotic delivery study treatments

All mice received 5 mg/kg dexamethasone, 7 days a week, for one week prior to and two weeks post infection with M. abscessus. Three groups of mice were included: a control group that did not receive antibiotic, one group that received biapenem intranasally, and the other subcutaneously. Treatment with biapenem (intranasal and subcutaneous dosing 300 mg/kg, q12) was initiated one week following infection and administered for one week. For subcutaneous injection, a 200 uL bolus of biapenem in 1x PBS was delivered twice daily via 26 G syringe. For intranasal dosing, a total of 40 uL of biapenem in 1x PBS was administered twice daily, 20 uL per nostril using 20 uL pipette, separated by 10 minutes to allow for absorption/clearance of drug. Mice were sacrificed 24 hours post infection (D0) to enumerate implantation, at 1 week post infection to enumerate bacterial burden prior to antibiotic treatment period, and then at 2 weeks post infection/1 week post antibiotic treatment to evaluate treatment efficacies. The treatment outline for this study is shown in Fig. 1B.

Details on the methods of histology preparation, pathology analysis, and statistical methods can be found in the supplemental information.

Results

Bacterial burden

After infection mice in all groups had an equivalent starting pulmonary implantation of ~3 log10 CFU of M. abscessus. In mice untreated with corticosteroid, M. abscessus lung burden remained steady at one week following infection but was gradually cleared thereafter, reaching an undetectable level at the five week time-point (Fig. 2, Table 1). In mice that received corticosteroid, M. abscessus lung burden increased throughout the treatment period. In the cortisone treatment groups this increase occurred at a slower rate than the dexamethasone treatment groups.

Figure 2.

Figure 2

Open in a new tab

M. abscessus burden in the lungs of mice receiving different corticosteroid treatments. Horizontal bars designate the duration of the treatment conditions relative to sacrifice time points. Plot of mean lung log10 CFU.

Table 1.

M. abscessus burden in the lungs of mice receiving different corticosteroid treatments.

Treatment Group Mean log10 CFU/Lung ± SD
Treatment Period Post Treatment Period
D0 Wk1 Wk3 Wk5 Wk7
Untreated (UN) 3.3 ± 0.1 (n = 5) 3.2 ± 0.8 (n = 5) 0.9 ± 0.9 (n = 5) 0.0 ± 0.0 (n = 5) 0.0 ± 0.0 (n = 5)
CNA 3.3 ± 0.2 (n = 5) 3.9 ± 1.0 (n = 5) 4.6 ± 0.9 (n = 5) 1.1 ± 1.1 (n = 5) 0.9 ± 1.3 (n = 5)
CNB 3.0 ± 0.7 (n = 5) 1.2 ± 1.1 (n = 5)
DXA 3.4 ± 0.1 (n = 5) 4.8 ± 0.7 (n = 5) 6.5 ± 0.5 (n = 5) 3.3 ± 0.5 (n = 5) 4.6 ± 0.2 (n = 4)
DXB 3.4 ± 0.2 (n = 4) 5.6 ± 0.3 (n = 5) 7.1 ± 1.4 (n = 5) 2.9 ± 1.0 (n = 5) 3.3 ± 2.1 (n = 2)
DXC 4.7 ± 1.0 (n = 5) 6.0 ± 0.9 (n = 5) 3.0 ± 0.4 (n = 5) 1.2 ± 1.1 (n = 5)
Open in a new tab

All groups began with equivalent lung implantation burdens. D0 refers to day mice were infected with M. abscessus, and WkX refers to X weeks following infection.

Following cessation of corticosteroid administration, M. abscessus lung burden declined in all groups with the exception of the DXA group where we observed a slight increase in CFU between 5 and 7 week time-points. In the cortisone treated mice, group CNB, which received an additional week of half-dose cortisone taper, M. abscessus lung burden was ~2 log10 higher at the week 5 time-point compared to CNA which did not have a steroid taper. However, by the 7 week time-point, M. abscessus was almost completely cleared by both groups of mice.

To assess the effect of dexamethasone on M. abscessus lung burden, we included three different groups with distinct dosing regimens (Fig. 1A). Mice in group DXA, which received a daily dose of 5 mg/kg dexamethasone, exhibited a robust growth of M. abscessus in the lungs during the treatment phase and lowest rate of clearance during treatment discontinuation phase.

We observed the most rapid M. abscessus proliferation, highest M. abscessus burden (Fig. 2, Table 1) and higher levels of morbidity in DXB group mice necessitating sacrifice of two mice at 3.5 week time-point and one mortality at the week 4 time-point. This group received the highest overall dexamethasone dose. We had one mortality at the 3.5 week time-point in the DXA group as well. Mice in the DXC group, which received intermittent dexamethasone following M. abscessus infection, demonstrated a steep decline in CFU once treatment was discontinued.

To explore the extra-pulmonary bacterial burden that may occur as part of these corticosteroid regimens, we enumerated the M. abscessus burden in the liver and spleen as well. M. abscessus burden at these sites also increased over time (Tables S2 and S3), although was variable across and within groups. The peak disseminated M. abscessus burden occurred at week 5 post-infection, after the period of peak bacterial burden in the lungs and once all corticosteroid treatments had ceased (Fig. S4).

Pathology

The number and proportion of lesions in the lungs of mice in cortisone, dexamethasone or untreated mice are summarized in Table 2. Prior to the week 3 time-point, we were unable to observe any evidence of lung pathology in all treatment groups. At the week 3 time-point, only mice in the DXA group developed lesions in their lungs. The lesion observed at this time-point was small but harbored high numbers of M. abscessus bacilli (Fig. 3A–C) consistent with CFU for this time point (Fig. 2). It is notable that compared to all other treatment groups, DXA had the most consistent presence of pathology in the standard section at the week 5 and week 7 time-points. One mouse at week 5 developed a large necrotic lesion with abscesses, which included large numbers of bacilli and early organizing fibrosis observable on Masson’s trichrome sections (Fig. S5). Large numbers of neutrophils were also identified in this lesion as well as macrophages and lymphocytes. Other standard sections from this time point had more mild pathology, more closely resembling observations at week 3. At week 7, one individual had a granuloma containing macrophages and lymphocytes, but less necrosis was observed and neutrophils were less common. Bacilli were also present in the lesion, but were sparse compared to the necrotic lesions, and there was no organizing fibrosis (Fig. 3D–F).

Table 2.

Quantification of lesions from a standardized section of lung tissue.

Time point/ Treatment Wk3 Avg % Lesion Wk5 Avg % Lesion Wk7 Avg % Lesion
UN 0/2 — 0/5 — 0/5 —
CNA 0/2 — 1/5 2.54 1/5 0.93
CNB 0/5 — 1/5 4.16
DXA 1/2 1.43 3/5 23.90 2/4 4.37
DXB 0/2 — 3/5 23.70 1/2 69.84
DXC 0/2 — 3/5 3.90 1/5 5.58
Open in a new tab

X/Y indicates the number of individuals sampled at the time point that had a lesion in the standardized section. “Avg % Lesion” is the average percentage of the section that was lesion, across the sampled mice that had lesions. No pathology was observed prior to the week 3 timepoint.

Figure 3.

Figure 3

Open in a new tab

Lung histology images from the DXA treatment group examined with Hematoxylin & Eosin (H&E), Acid fast bacilli (AFB) and Masson Trichrome (MAS) stains. Lesions observed in H&E are designated with arrows. AFB stains M. abscessus purple/red and some of the stained rods are indicated using arrowheads. MAS stains collagen blue to investigate any irregular collagen deposition and fibrosis. At week 3 there was one small lesion on H&E (A) with high bacterial burden observable (B), low levels of immune infiltrate and no fibrosis (C). At week 7 we observed an organized histiocytic granuloma, with lymphocytic infiltrate observable at higher magnification (inset, D). There were low numbers of bacilli present which all appeared to be intracellular (E) and no fibrosis (F). (H&E insets 50x magnification).

The lungs of mice in the DXC group had pathology similar in appearance to the non-necrotic lesions in the DXA mice but were infrequent (Fig. S6). In contrast to the controlled histiocytic granulomas observed in DXA and DXC, DXB trended towards necrosis with large numbers of neutrophils and abundant intracellular (in macrophages) and extracellular bacilli (Fig. S7). Neutrophilia was especially apparent in one mouse in which vasculature was occluded with neutrophils and fewer lymphocytes. Mice in both cortisone administered groups had a low lesion burden compared to dexamethasone treatment groups. Few gross pathological lesions could be observed on the lungs with the exception of moribund mice.

Application in antibiotic evaluation

Biapenem is a broad-spectrum β-lactam of the carbapenem subclass34 with demonstrated in vitro activity against M. abscessus, with an MIC of 16 μg/mL35. It is not currently FDA approved, but is approved for use in Japan. To evaluate the utility of the mouse model to test antibiotics via alternate routes of administration we immunosuppressed the mice using the DXA regimen and treated mice with biapenem administered either subcutaneously or intranasally. Compared to the control group that did not receive antibiotic, the lung M. abscessus burden was reduced by ~2 log10 at the completion of one week of twice daily treatment with biapenem. The efficacy of biapenem in reducing M. abscessus lung burden was indistinguishable between the two routes of administrations (Fig. 4). This and our previous study demonstrate proof-of-concept of utility of this mouse model for various routes of delivering antibiotics against M. abscessus.

Figure 4.

Figure 4

Open in a new tab

Investigation into intranasal administration of biapenem in the DXA model of M. abscessus infection. Mean ± SD lung log10 CFU in mice that did not receive biapenem (−), subcutaneously delivered biapenem (SB), and intranasally delivered biapenem groups (IB), after one week of treatment. (*p < 0.05).

Infection with clinical M. abscessus isolates

Lung burdens of all six isolates one day following aerosolization, a measure of their ability to implant and establish infection, were similar to that of the reference strain ATCC 19977 (Fig. 5, Tables S4 and 1 for ATCC 19977 data). At one week following infection strains 202, 214, JHH4, and JHHKB had increases in average log10 CFU, while strains 5 N and 215 appeared to be stable over this time period. At three weeks following infection the bacterial burden with strains 202, 214, JHH4, and JHHKB continued to increase. Strains 5 N and 215 had a modest increase in average log10 CFU at this time point, but with a large variability in the strain 215 group due to one mouse having no CFU isolated from the lung homogenate at this time point.

Figure 5.

Figure 5

Open in a new tab

Burden of six clinical M. abscessus isolates in the lungs of mice. Plot of mean lung log10 CFU.

Discussion

There are currently no FDA approved antibiotics to treat M. abscessus pulmonary disease and recommended treatment regimens are largely ineffective, necessitating a minimum treatment duration of at least 12 months following sputum culture conversion3,36, often with cytotoxic antibiotics that are poorly-tolerated by patients. The need to accelerate and improve preclinical testing of novel antibiotics and regimens for M. abscessus pulmonary infections is urgent. Our aim was to meet the need for an animal model that more closely recapitulated pulmonary M. abscessus disease in humans so that it could be used as a tool to study drug efficacy against M. abscessus. As mouse models have contributed extensively to the study of pulmonary disease by another mycobacterium, M. tuberculosis15–17,37, we again leveraged the mouse to develop a model of pulmonary M. abscessus infection that utilized the aerosol route for infection, led to an increase in lung bacterial burden after implantation, and resulted in the development of relevant pulmonary pathology.

Administration of the corticosteroids cortisone or dexamethasone led to an increase in lung M. abscessus burden post-implantation across all dosing strategies. However, the rate of increase in M. abscessus burden was slower in mice that received cortisone, resulting in lower peak burden and corresponding lack of lung pathology. In prior experiments with cortisone treatment that reached a higher bacterial burden, pathology was observed (Fig. S2E). Further investigation of pathology in mice treated with cortisone compared to dexamethasone is warranted to determine whether one corticosteroid is preferable for relevant pathology development, and highlights the need for investigations into other immunomodulatory agents as well.

Following cessation of corticosteroid administration, we observed a decrease in M. abscessus burden in the lungs across all groups at the week 5 time-point. An enhanced immune response post-steroid removal in the form of increased infiltration of neutrophils and lymphocytes was consistently observed. Corticosteroids like dexamethasone are known to have many immune-modulatory effects that vary by cell type. The relationship between glucocorticoids and T-lymphocytes is complex, but there appears to be a consensus in the literature that glucocorticoids lead to thymocyte apoptosis, with subsequent decrease in immature T-cell counts38–41 and skewing of the T-cell response toward Th241–43. In addition, we hypothesize that corticosteroid treatment in mice reduced migration of neutrophils from the blood into the lungs, coupled with reductions in superoxide and reactive oxygen species, which may have allowed M. abscessus to proliferate unimpaired44–47. No animal model is able to comprehensively simulate all aspects of human infection and pathology, nor does any one model meet all investigative goals within. As investigations into host-directed therapies and immunomodulatory therapies move forward against M. abscessus infections48, other models that do not have immune system manipulation as a limitation are necessary.

We found administration of 5 mg/kg dexamethasone once daily (DXA) to be the most promising dosing strategy, as this dosing regimen was well-tolerated in the mice and achieved the desired high level of lung M. abscessus burden with extended duration of infection. The duration of persistence of pulmonary M. abscessus infection using the DXA regimen following discontinuation of dexamethasone, as well as the mechanistic basis for the observed rebound in infection were beyond the scope of the current proof-of-concept study. Regardless, the extended period of lung M. abscessus burden provides valuable extra time for the evaluation of efficacy of antibiotics. We undertook additional proof-of-concept studies of the DXA dosing strategy with M. abscessus clinical isolates and in Balb/c mice. Clinical isolates demonstrated variable ability to replicate in vivo compared to the reference strain, while Balb/c mice developed a similar increase in lung M. abscessus burden post-implantation (Fig. S8). Pathology development and CFU trends following steroid cessation were not evaluated in these short studies, but these data suggest that the DXA dosing strategy may be utilized in multiple murine strains and with other strains of M. abscessus.

In our prior studies, persistent use of steroids did not produce defined granulomas characterized by organized migration and localization of immune cells and instead resulted in a necrotizing pneumonia (Fig. S1C–H). By contrast, upon removal of corticosteroids, we observed pathology ranging from small granulomas to extensive necrosis and abscessation (Fig. S2E). In the current study, the pathology observed in dexamethasone-administered groups followed a general pattern of lesions with higher bacterial burdens being more necrotic and neutrophil-rich with associated macrophages, lymphocytes, and organizing fibrosis; whereas lesions with lower bacterial burdens had less neutrophilic infiltrate and little fibrosis, but still contained foamy macrophages and lymphocytic infiltrate. This suggests that pathologic lesions resulting from M. abscessus infection may exhibit similar lesion typology as has been described for M. tuberculosis infections in C3HeB/FeJ mice16. It is worthwhile to note that mice not found to have lesions in standardized lung sections does not preclude the presence of lesions in other levels of the lung; however, in order to reduce bias in selection of lesions for analysis, this method of histology preparation was performed. An extensive characterization of pathology and associated immune response and dynamics of lung M. abscessus burden over longer durations was beyond the scope the current study.

The model described in this study recapitulates salient hallmarks of pulmonary M. abscessus disease in humans such as the natural route of infection, proliferation of M. abscessus and persistence of infection resulting in organized lesions with involvement of macrophages, neutrophils, and lymphocytes. This model allows for evaluation of efficacies of antimicrobial chemotherapies that may be administered via various routes and therefore addresses the current need for an animal model for preclinical development of drugs and regimens to treat M. abscessus infection. Evidence that this model is amenable to the use of more antibiotic resistant clinical isolates also increases its functionality for preclinical drug testing. As this was a proof-of-concept study, additional studies are warranted to further characterize the immune pathology and infection dynamics over a longer duration.

Supplementary information

Supplemental Figures and Tables. (71.1MB, pdf)
Supplemental Methods. (36.4KB, pdf)

Acknowledgements

This work was supported by the Cystic Fibrosis Foundation grant LAMICH17GO and NIH R21 award AI137720 to GL. NIH-NIAID R01AI106733 and TBRU-U19AI111224 to RJB. ECM was supported by the NIH F31 award HL147392 and ESR was supported by the NIH T32 award AI007291. We would like to thank Dr. Nicole Ammerman and Dr. Eric Nuermberger of Johns Hopkins University for participating in meetings to discuss these studies. We would also like to thank Dr. Kiera Cohen, Johns Hopkins University, for reviewing this manuscript.

Author contributions

E.C.M. and G.L. devised the study. E.C.M., E.S.R. and G.L. performed the mouse experiments. J.M., P.I. and R.B. performed the pathology analysis. E.C.M. and G.L. wrote the manuscript and all authors were involved in its revision and approval.

Competing interests

The authors declare no competing interests.

Footnotes

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

is available for this paper at 10.1038/s41598-020-60452-1.

References

  • 1.Olivier KN, et al. Nontuberculous mycobacteria: I: Multicenter prevalence study in cystic fibrosis. Am. J. Respir. Crit. Care Med. 2003;167:828–834. doi: 10.1164/rccm.200207-678OC. [DOI] [PubMed] [Google Scholar]
  • 2.Leung JM, Olivier KN. Nontuberculous mycobacteria: The changing epidemiology and treatment challenges in cystic fibrosis. Curr. Opin. Pulm. Med. 2013;19:662–669. doi: 10.1097/MCP.0b013e328365ab33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Griffith DE, et al. An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am. J. Respir. Crit. Care Med. 2007;175:367–416. doi: 10.1164/rccm.200604-571ST. [DOI] [PubMed] [Google Scholar]
  • 4.Esther CR, Esserman DA, Gilligan P, Kerr A, Noone PG. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J. Cyst. Fibros. 2010;9:117–123. doi: 10.1016/j.jcf.2009.12.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Benwill JL, Wallace RJ. Mycobacterium abscessus: Challenges in diagnosis and treatment. Curr. Opin. Infect. Dis. 2014;27:506–510. doi: 10.1097/QCO.0000000000000104. [DOI] [PubMed] [Google Scholar]
  • 6.Jarand J, et al. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin. Infect. Dis. 2011;52:565–571. doi: 10.1093/cid/ciq237. [DOI] [PubMed] [Google Scholar]
  • 7.Pryjma M, Burian J, Thompson CJ. Rifabutin acts in synergy and is bactericidal with frontline Mycobacterium abscessus antibiotics clarithromycin and tigecycline, suggesting a potent treatment combination. Antimicrob. Agents Chemother. 2018;62:1–27. doi: 10.1128/AAC.00283-18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Lavollay M, et al. In vitro activity of cefoxitin and imipenem against Mycobacterium abscessus complex. Clin. Microbiol. Infect. 2014;20:7–10. doi: 10.1111/1469-0691.12405. [DOI] [PubMed] [Google Scholar]
  • 9.Shoen, C., Benaroch, D., Sklaney, M. & Cynamon, M. In vitro activities of omadacycline against rapidly growing mycobacteria. Antimicrob. Agents Chemother., 10.1128/AAC.02522-18 (2019). [DOI] [PMC free article] [PubMed]
  • 10.Kaushik A, Ammerman NC, Martins O, Parrish NM, Nuermberger EL. In vitro activity of new tetracycline analogs omadacycline and eravacycline against drug-resistant clinical isolates of Mycobacterium abscessus. Antimicrob. Agents Chemother. 2019;63:2–6. doi: 10.1128/AAC.00470-19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Pandey R, et al. Dual β-Lactam Combinations Highly Active against Mycobacterium abscessus Complex. In Vitro. MBio. 2019;10:1–11. doi: 10.1128/mBio.02895-18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Lindman, M. & Dick, T. Bedaquiline eliminates bactericidal activity of β-lactams against Mycobacterium abscessus. Antimicrob. Agents Chemother, 10.1128/aac.00827-19 (2019). [DOI] [PMC free article] [PubMed]
  • 13.Run EL, Arthur M, Mainardi J. In Vitro and Intracellular Activity of Imipenem Combined with Rifabutin and Avibactam against Mycobacterium abscessus. Antimicrob. Agents Chemother. 2018;62:1–8. doi: 10.1128/AAC.00623-18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Rosenthal IM, et al. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob. Agents Chemother. 2012;56:4331–4340. doi: 10.1128/AAC.00912-12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Driver ER, et al. Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2012;56:3181–3195. doi: 10.1128/AAC.00217-12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Irwin SM, et al. Presence of multiple lesion types with vastly different microenvironments in C3HeB/FeJ mice following aerosol infection with Mycobacterium tuberculosis. Dis. Model. Mech. 2015;8:591–602. doi: 10.1242/dmm.019570. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Lanoix J-P, Lenaerts AJ, Nuermberger EL. Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis. Dis. Model. Mech. 2015;8:603–610. doi: 10.1242/dmm.019513. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Obregón-Henao A, et al. Susceptibility of Mycobacterium abscessus to antimycobacterial drugs in preclinical models. Antimicrob. Agents Chemother. 2015;59:6904–6912. doi: 10.1128/AAC.00459-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Ordway D, et al. Animal model of Mycobacterium abscessus lung infection. J. Leukoc. Biol. 2008;83:1502–1511. doi: 10.1189/jlb.1007696. [DOI] [PubMed] [Google Scholar]
  • 20.De Groote MA, et al. GM-CSF knockout mice for preclinical testing of agents with antimicrobial activity against Mycobacterium abscessus. J. Antimicrob. Chemother. 2014;69:1057–1064. doi: 10.1093/jac/dkt451. [DOI] [PubMed] [Google Scholar]
  • 21.N’Goma JCB, et al. Mycobacterium abscessus phospholipase C expression is induced during coculture within amoebae and enhances M. abscessus virulence in mice. Infect. Immun. 2015;83:780–791. doi: 10.1128/IAI.02032-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Le Moigne V, et al. Bacterial phospholipases C as vaccine candidate antigens against cystic fibrosis respiratory pathogens: The Mycobacterium abscessus model. Vaccine. 2015;33:2118–2124. doi: 10.1016/j.vaccine.2015.03.030. [DOI] [PubMed] [Google Scholar]
  • 23.Batten C, McCune RM. The influence of corticotrophin and cortisone with antituberculous drugs on populations of Mycobacterium tuberculosis in tissues of mice. Br. J. Exp. Pathol. 1957;38:424–437. [PMC free article] [PubMed] [Google Scholar]
  • 24.Scanga CA, et al. Reactivation of Latent Tuberculosis: Variations on the Cornell Murine Model. 1999;67:4531–4538. doi: 10.1128/iai.67.9.4531-4538.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Wallace RJ, Brown BA, Onyi GO. Skin, Soft Tissue, and Bone Infections Due to Mycobacterium chelonae chelonae : Importance of Prior Corticosteroid Therapy, Frequency of Disseminated Infections, and Resistance to Oral Antimicrobials Other than Clarithromycin. J. Infect. Dis. 1992;166:405–412. doi: 10.1093/infdis/166.2.405. [DOI] [PubMed] [Google Scholar]
  • 26.Falkinham JO. Epidemiology of Infection by Nontuberculous Mycobacteria. Clin. Microbiol. Rev. 1996;9:177–215. doi: 10.1128/CMR.9.2.177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Ingram CW, Tanner DC, Durack DT, Kernodle GWJ, Corey GR. Disseminated Infection with Rapidly Growing Mycobacteria. Clin. Infect. Dis. 1993;16:463–471. doi: 10.1093/clind/16.4.463. [DOI] [PubMed] [Google Scholar]
  • 28.Story-Roller E, Maggioncalda EC, Lamichhane G. Synergistic efficacy of β-lactam combinations against Mycobacterium abscessus pulmonary infection in mice. Antimicrob. Agents Chemother. 2019;63:1–12. doi: 10.1128/AAC.00614-19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Olivier KN, et al. Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease. Am. J. Respir. Crit. Care Med. 2017;195:814–823. doi: 10.1164/rccm.201604-0700OC. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Kaushik A, et al. Combinations of avibactam and carbapenems exhibit enhanced potencies against drug-resistant Mycobacterium abscessus. Future Microbiol. 2017;12:473–480. doi: 10.2217/fmb-2016-0234. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Martins TG, et al. Corticosteroid-Induced Immunosuppression Ultimately Does Not Compromise the Efficacy of Antibiotherapy in Murine Mycobacterium ulcerans Infection. PLoS Negl. Trop. Dis. 2012;6:1–8. doi: 10.1371/journal.pntd.0001925. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Zhang M, et al. Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice. Am. J. Respir. Crit. Care Med. 2011;183:1254–1261. doi: 10.1164/rccm.201012-1949OC. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Martins, T. G. et al. Local and regional re-establishment of cellular immunity during curative antibiotherapy of murine Mycobacterium ulcerans infection. PLoS One7 (2012). [DOI] [PMC free article] [PubMed]
  • 34.Perry CM, Ibbotson T. Biapenem. Drugs. 2002;62:2221–2234. doi: 10.2165/00003495-200262150-00005. [DOI] [PubMed] [Google Scholar]
  • 35.Kaushik A, et al. Carbapenems and Rifampin exhibit synergy against Mycobacterium tuberculosis and Mycobacterium abscessus. Antimicrob. Agents Chemother. 2015;59:6561–6567. doi: 10.1128/AAC.01158-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Haworth, C. S. et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax72 (2017). [DOI] [PubMed]
  • 37.Kramnik I, Beamer G. Mouse models of human TB pathology: roles in the analysis of necrosis and the development of host-directed therapies. Semin. Immunopathol. 2016;38:221–237. doi: 10.1007/s00281-015-0538-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Marchetti MC, Di Marco B, Cifone G, Migliorati G, Riccardi C. Dexamethasone-induced apoptosis of thymocytes: Role of glucocorticoid receptorassociated Src kinase and caspase-8 activation. Blood. 2003;101:585–593. doi: 10.1182/blood-2002-06-1779. [DOI] [PubMed] [Google Scholar]
  • 39.Cifone MG, et al. Dexamethasone-Induced Thymocyte Apoptosis: Apoptotic Signal Involves the Sequential Activation of Phosphoinositide-Specific Phospholipase C, Acidic Sphingomyelinase, and Caspases. Blood. 1999;93:2282–2296. doi: 10.1182/blood.V93.7.2282. [DOI] [PubMed] [Google Scholar]
  • 40.Ansar Ahmed S, Sriranganathan N. Differential effects of dexamethasone on the thymus and spleen: alterations in programmed cell death, lymphocyte subsets and activation of T cells. Immunopharmacology. 1994;28:55–66. doi: 10.1016/0162-3109(94)90039-6. [DOI] [PubMed] [Google Scholar]
  • 41.Ashwell JD, Lu FWM, Vacchio MS. Glucocorticoids in T Cell Development and Function. Annu. Rev. Immunol. 2000;18:309–345. doi: 10.1146/annurev.immunol.18.1.309. [DOI] [PubMed] [Google Scholar]
  • 42.Ramírez F. Glucocorticoids Induce a TH2 Response In Vitro. Dev. Immunol. 1998;6:233–243. doi: 10.1155/1998/73401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Ramírez F, Fowell DJ, Puklavec M, Simmonds S, Mason D. Glucocorticoids promote a TH2 cytokine response by CD4+ T cells in vitro. J. Immunol. 1996;156:2406–12. [PubMed] [Google Scholar]
  • 44.Ronchetti S, Ricci E, Migliorati G, Gentili M, Riccardi C. How Glucocorticoids Affect the Neutrophil Life. Int. J. Mol. Sci. 2018;19:4090. doi: 10.3390/ijms19124090. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Dandona P, et al. Effect of dexamethasone on reactive oxygen species generation by leukocytes and plasma interleukin-10 concentrations: A pharmacodynamics study. Clin. Pharmacol. Ther. 1999;66:58–65. doi: 10.1016/S0009-9236(99)70054-8. [DOI] [PubMed] [Google Scholar]
  • 46.Filep JG, Delalandre A, Payette Y, Foldes-Filep E. Glucocorticoid receptor regulates expression of L-selectin and CD11/CD18 on human neutrophils. Circulation. 1997;96:295–301. doi: 10.1161/01.CIR.96.1.295. [DOI] [PubMed] [Google Scholar]
  • 47.Cox G. Glucocorticoid treatment inhibits apoptosis in human neutrophils. Separation of survival and activation outcomes. J. Immunol. 1995;154:4719–25. [PubMed] [Google Scholar]
  • 48.Scott JP, Ji Y, Kannan M, Wylam ME. Inhaled granulocyte–macrophage colony-stimulating factor for Mycobacterium abscessus in cystic fibrosis. Eur. Respir. J. 2018;51:1702127. doi: 10.1183/13993003.02127-2017. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplemental Figures and Tables. (71.1MB, pdf)
Supplemental Methods. (36.4KB, pdf)

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES